The NASDAQ-listed company can access discretionary funds through a 36-month agreement with New Jersey’s Yorkville Advisors.
Irish health diagnostic solutions company Trinity Biotech has secured new funding of up to $25m through a standby equity purchase agreement (SEPA), with proceeds going towards R&D programmes and commercialisation initiatives.
The SEPA deal in conjunction with Yorkville Advisors – based in New Jersey, US – gives Trinity Biotech the option, but with no obligation, to sell up to $25m of newly issued American depositary shares to Yorkville at its discretion over a period of up to 36 months.
John Gillard, Trinity Biotech president and CEO, said: “Our key strategic objectives at Trinity Biotech are to grow our existing business profitably and to advance our exciting innovation agenda, including our flagship development CGM+.”
CGM+ is the company’s new continuous glucose monitoring platform, currently in the later stages of device development, which uses a “proprietary needle-free glucose sensor” that eliminates the need for “finger-stick calibration” by users, the company said.
“This financing agreement provides us with significant additional capability to progress these objectives,” Gillard added.
NASDAQ-listed Trinity Biotech, based in Bray, Co Wicklow, is a commercial stage biotech company focused on diabetes management solutions and human diagnostics, including wearable biosensors. It sells direct in the US and through a network of distributors and partners in more than 75 countries.
The company reported revenues of $48.6m over a trailing 12-month period ended September 30 2025, and said it expects continued operational and financial progress into 2026, based in significant part on it catering to continued global demand for HIV testing provisions.
Innovations currently in development at Trinity Biotech include a cancer monitoring technology and a biomarker-based bioinformatics diagnostic platform.
In April 2023, Trinity Biotech agreed to sell its life sciences supply business to Switzerland’s Biosynth for $30m. A year earlier, a $45m investment in the Trinity Biotech from South Korea’s MiCo saw it take a 29.9pc share of the Irish company.
Don’t miss out on the knowledge you need to succeed. Sign up for the Daily Brief, Silicon Republic’s digest of need-to-know sci-tech news.
